- Report
- March 2024
- 185 Pages
Global
From €3253EUR$3,374USD£2,782GBP
€3614EUR$3,749USD£3,091GBP
- Report
- February 2024
- 250 Pages
Global
From €4821EUR$5,000USD£4,123GBP
- Report
- February 2024
- 250 Pages
Global
From €4821EUR$5,000USD£4,123GBP
- Report
- February 2024
- 250 Pages
Global
From €4821EUR$5,000USD£4,123GBP
- Report
- February 2024
- 250 Pages
Global
From €4821EUR$5,000USD£4,123GBP
- Report
- April 2024
- 136 Pages
Global
From €3759EUR$3,899USD£3,215GBP
- Drug Pipelines
- April 2024
- 202 Pages
Global
From €7665EUR$7,950USD£6,555GBP
- Report
- March 2024
- 134 Pages
Global
From €7665EUR$7,950USD£6,555GBP
- Report
- October 2023
- 189 Pages
Global
From €4724EUR$4,900USD£4,040GBP
- Report
- October 2023
- 185 Pages
Global
From €4724EUR$4,900USD£4,040GBP
- Drug Pipelines
- April 2024
- 40 Pages
Global
From €1205EUR$1,250USD£1,031GBP
- Report
- November 2023
- 224 Pages
Global
From €7231EUR$7,500USD£6,184GBP
- Report
- October 2023
- 145 Pages
Global
From €3037EUR$3,150USD£2,597GBP
- Report
- June 2023
- 76 Pages
Middle East, Africa
From €1446EUR$1,500USD£1,237GBP
- Report
- May 2022
- 330 Pages
Global
From €2892EUR$3,000USD£2,474GBP
- Report
- February 2022
- 360 Pages
United States
From €3471EUR$3,600USD£2,968GBP
- Report
- July 2022
- 461 Pages
Global
From €4780EUR$5,132USD£3,950GBP
- Report
- July 2018
- 77 Pages
Global
From €5736EUR$5,950USD£4,906GBP
- Report
- August 2022
- 118 Pages
Global
From €4579EUR$4,750USD£3,917GBP
- Report
- August 2022
- 115 Pages
Global
From €4579EUR$4,750USD£3,917GBP
Rituximab is a monoclonal antibody used to treat a variety of immune disorders, including rheumatoid arthritis, systemic lupus erythematosus, and non-Hodgkin's lymphoma. It works by targeting and destroying B-cells, which are a type of white blood cell involved in the body's immune response. Rituximab is administered intravenously and is often used in combination with other drugs.
Rituximab is a relatively new drug, having been approved by the US Food and Drug Administration in 1997. Since then, it has become a popular treatment for immune disorders, due to its effectiveness and relatively low side effects. It is also used off-label to treat a variety of other conditions, such as multiple sclerosis and vasculitis.
The market for rituximab is highly competitive, with several major pharmaceutical companies producing the drug. These include Roche, Merck, Pfizer, and Biogen. Additionally, there are several generic versions of the drug available, produced by companies such as Sandoz and Teva Pharmaceuticals. Show Less Read more